 C4X Discovery Holdings PLC AIM:C4XD C4XD has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to US402mln, for developing and commercialising its NRF2 Activator programme. AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease COPD. 